What is Roth Capital's Estimate for CervoMed Q1 Earnings?

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Analysts at Roth Capital reduced their Q1 2025 EPS estimates for shares of CervoMed in a research report issued to clients and investors on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings of ($0.80) per share for the quarter, down from their previous forecast of ($0.52). Roth Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed's Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($2.47) EPS.

CervoMed (NASDAQ:CRVO - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.13). CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. The company had revenue of $2.16 million during the quarter, compared to analyst estimates of $1.51 million.

CRVO has been the topic of several other research reports. D. Boral Capital reissued a "buy" rating and set a $10.00 price objective on shares of CervoMed in a research note on Monday, March 17th. Canaccord Genuity Group increased their price target on CervoMed from $12.00 to $21.00 and gave the stock a "buy" rating in a research note on Tuesday, March 18th. Brookline Capital Management upgraded CervoMed from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th. Jones Trading upgraded CervoMed from a "hold" rating to a "buy" rating and set a $15.00 target price for the company in a research note on Thursday, March 13th. Finally, Morgan Stanley reissued an "underweight" rating on shares of CervoMed in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, CervoMed presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.50.

Remove Ads

CervoMed Trading Down 25.1 %

Shares of CervoMed stock traded down $3.58 during mid-day trading on Thursday, hitting $10.71. 3,132,132 shares of the stock were exchanged, compared to its average volume of 1,226,604. The stock has a market capitalization of $66.08 million, a price-to-earnings ratio of -5.28 and a beta of 1.84. CervoMed has a twelve month low of $1.80 and a twelve month high of $25.92. The company has a 50-day simple moving average of $3.47 and a 200 day simple moving average of $7.72.

Hedge Funds Weigh In On CervoMed

Several hedge funds and other institutional investors have recently modified their holdings of CRVO. Woodline Partners LP acquired a new stake in CervoMed during the 4th quarter worth approximately $175,000. Nuveen Asset Management LLC raised its stake in shares of CervoMed by 113.6% in the 4th quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company's stock valued at $97,000 after acquiring an additional 22,104 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of CervoMed during the 4th quarter valued at $32,000. Mariner LLC purchased a new stake in CervoMed during the 4th quarter worth $30,000. Finally, DRW Securities LLC acquired a new stake in CervoMed in the 4th quarter valued at $30,000. 25.15% of the stock is owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.